ASAS/EULAR recommendations for the management of ankylosing spondylitis.

Rheumazentrum-Ruhrgebiet, St Josefs-Krankenhaus, Landgrafenstr 15, 44652 Herne, Germany.
Annals of the Rheumatic Diseases (Impact Factor: 9.11). 05/2006; 65(4):442-52. DOI: 10.1136/ard.2005.041137
Source: PubMed

ABSTRACT To develop evidence based recommendations for the management of ankylosing spondylitis (AS) as a combined effort of the 'ASsessment in AS' international working group and the European League Against Rheumatism.
Each of the 22 participants was asked to contribute up to 15 propositions describing key clinical aspects of AS management. A Delphi process was used to select 10 final propositions. A systematic literature search was then performed to obtain scientific evidence for each proposition. Outcome data for efficacy, adverse effects, and cost effectiveness were abstracted. The effect size, relative risk, number needed to treat, and incremental cost effectiveness ratio were calculated. On the basis of the search results, 10 major recommendations for the management of AS were constructed. The strength of recommendation was assessed based on the strength of the literature evidence, risk-benefit trade-off, and clinical expertise.
The final recommendations considered the use of non-steroidal anti-inflammatory drugs (NSAIDs) (conventional NSAIDs, coxibs, and co-prescription of gastroprotective agents), disease modifying antirheumatic drugs, treatments with biological agents, simple analgesics, local and systemic steroids, non-pharmacological treatment (including education, exercise, and physiotherapy), and surgical interventions. Three general recommendations were also included. Research evidence (categories I-IV) supported 11 interventions in the treatment of AS. Strength of recommendation varied, depending on the category of evidence and expert opinion.
Ten key recommendations for the treatment of AS were developed and assessed using a combination of research based evidence and expert consensus. Regular updating will be carried out to keep abreast of new developments in the management of AS.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Home exercise is often recommended for management of patients with ankylosing spondylitis (AS); however, what kind of home exercise is more beneficial for patients with AS has not been determined yet. We aimed to compare the effectiveness of combined home exercise (COMB) and range-of-motion home exercise (ROM) in patients with AS. Nineteen subjects with AS completed either COMB (n = 9) or ROM (n = 10) program. The COMB program included range-of-motion, strengthening, and aerobic exercise while the ROM program consisted of daily range-of-motion exercise only. After exercise instruction, subjects in each group performed home exercise for 3 months. Assessment included cardiopulmonary exercise test, pulmonary function test, spinal mobility measurement, chest expansion, Bath Ankylosing Spondylitis Functional Index (BASFI), and other functional ability and laboratory tests. After exercise, the COMB group showed significant improvement in peak oxygen uptake (12.3%, P = 0.008) and BASFI (P = 0.028), and the changed score between pre- and postexercise data was significantly greater in the COMB group regarding peak oxygen uptake and BASFI. Significant improvement in finger-to-floor distance after 3-month exercise was found only in the COMB group (P = 0.033). This study demonstrates that a combined home exercise is more effective than range-of-motion home exercise alone in aerobic capacity and functional ability.
    BioMed Research International 01/2014; 2014:398190. · 2.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die ASAS/EULAR-Empfehlungen für die Behandlung der ankylosierenden Spondylitis sind im Jahr 2010 überarbeitet worden. Aufgrund des Expertenkonsens und der Evidenzlage wurden die ursprünglichen 10 Empfehlungen auf 11 Empfehlungen erweitert und zusätzlich eine Rubrik ,,übergeordnete Prinzipien“ eingeführt, in der grundlegende Aspekte der Erkrankung angesprochen werden. Im vorliegenden Bericht werden die Ergebnisse der Evaluation der deutschen Übersetzung dieser Empfehlungen vorgestellt. Insgesamt 25 Experten aus Deutschland, Österreich und der Schweiz haben die Übersetzung hinsichtlich des Grades der Empfehlung auf einer Skala zwischen 0 (keine Übereinstimmung) bis 10 (volle Übereinstimmung) bewertet. Die Übereinstimmung der Experten mit den Empfehlungen war insgesamt mit 9,6 ± 1,05 sehr hoch.
    Zeitschrift für Rheumatologie 01/2013; 72(1). · 0.45 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The objective of this study is to evaluate the responsiveness to therapy change of a global ultrasound (US) assessment in the short-term monitoring of spondyloarthritis (SpA) patients with peripheral involvement. Consecutive SpA patients with both clinical peripheral involvement and active disease (initiating or changing therapy) were included. All patients underwent both clinical and US assessment in day entering the study and after 3 months of follow-up. Peripheral global US assessment included the recognition of abnormal inflammatory findings at joint, tendon, and entheseal level according tostandardized scanning methods. A total of 34 patients completed both basal and 3-month follow-up assessments. Acute phase reactants, both erythrocyte sedimentation rate and C-reactive protein, tenderness (68) and swollen (66) joint counts, Bath Ankylosing Spondylitis Disease Activity Index and Health Assessment Questionnaire decreased significantly at 3-month follow-up. Total score for the global US assessment also decreased significantly between basal and 3-month follow-up assessment [mean difference, 12.33 (IC 95 %, 9.23-15.42); p < 0.0001]. All individual component, joint, tendon, and enthesis scores, also showed a significant decrease during the follow-up period. A high degree of intra-observer reliability was found for the global US assessment (ICC [95 % CI]: 0.977 [0.961-0.993]). This global US assessment, including joints, tendons, and entheses, showed a good responsiveness to clinical changes and might be useful for monitoring SpA patients with peripheral involvement.
    Clinical rheumatology. 05/2014;

Full-text (2 Sources)

Available from
May 16, 2014